MedTrace Logo

Correlation Research Study: IQ2, NcIQ and IQ101

NCT00491777 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2007-06-26

No results posted yet for this study

Summary

The new NcIQ thoracic impedance monitor is based on the predicate device, the IQ101. The new model uses the same 3-dimensional signal averaging as the original device, but also include second radio frequency signal to permit the device to work "wirelessly", i.e., without electrode lead attachments to the patient. This study seeks to 1) validate the use of the new device and confirm the correlation of the IQ101 and NcIQ. 2) Evaluate the ease of the new device.

The new IQ2 thoracic impedance monitor is based on the predicate device, the IQ101. The new model uses the same 3-dimensional signal averaging as the original device, but with smaller housing and updated operating software. This study seeks to 1) Validate the use of the new device and confirm the correlation of the IQ101 and IQ2. 2) Compare the ease of the devices.

Conditions

Interventions

DEVICE

Noninvasive Hemodynamic Patient Monitor

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • Shand's Medical Center

    collaborator UNKNOWN

  • Noninvasive Medical Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Kevin Ferguson, MD · Shand's Hospital

  • Joseph A Tyndall, MD · Shand's Hospital

  • David Seaberg, MD · Shand's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Completion
2007-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00491777 on ClinicalTrials.gov